At the 2019 meeting of the American Cancer Society of Clinical Oncologists (ASCO), Emily Bergsland, MD, University of California, San Francisco, reported on the results of a phase II clinical trial of pazopanib (PZ). The study evaluated how well PZ treats patients with advancing gastrointestinal neuroendocrine tumor (NETs), which were in the gut rather than the pancreas.
PZ is a drug taken orally that may stop or slow tumor growth by blocking cell processes required for the growth and expansion of the tumor cells. This clinical trial tested the efficacy of treating 171 study participants with either PZ or a placebo (inactive agent). Neither the patient nor the physician knew which treatment they received (PZ vs. placebo).
[npfButton size=“small” text=”Find out more” href=”https://netrf.org/2019/06/18/targeted-therapy-under-investigation/?utm_source=newsletter&utm_medium=email&utm_content=(MORE)&utm_campaign=June%202019%20eUpdate” background-colour=”#f06124″ text-colour=”#ffffff”]